Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | PLAU | P00749 | 7/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | SENP1 | Q9P0U3 | 2/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | F9 | P00740 | 1/20 | 0.48 |
| ▸ | PLAT | P00750 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | PLG | P00747 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5278381 | 0.89 | NR1H4 (0.54) | TRPV1SENP1NR1H4F9CNR1 | |
| SCHEMBL5293330 | 0.88 | DHODH (0.52) | PLAUTRPV1SENP1NR1H4F9 | |
| SCHEMBL13675994 | 0.85 | CA1 (0.64) | ALDH1A1HPGDLMNATRPV1NR1H4 | |
| SCHEMBL21549396 | 0.78 | TRPV1 (0.57) | TRPV1NR1H4 | |
| SCHEMBL21549370 | 0.78 | TRPV1 (0.60) | ALDH1A1HPGDTRPV1NR1H4SMN1; SMN2 | |
| SCHEMBL13675953 | 0.77 | KMT2A (0.62) | ALDH1A1HPGDLMNATRPV1NR1H4 | |
| SCHEMBL20625313 | 0.76 | MAPT (0.71) | LMNATRPV1NR1H4MAPT | |
| SCHEMBL13676043 | 0.76 | MAPT (0.71) | ALDH1A1LMNATRPV1NR1H4MAPT | |
| SCHEMBL13676191 | 0.75 | MEN1 (0.61) | ALDH1A1HPGDLMNATRPV1NR1H4 | |
| SCHEMBL13675947 | 0.75 | RAB9A (0.75) | ALDH1A1HPGDLMNATRPV1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863756-A1 | BIARYL DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-12 | — | — | EP | disclosed |
| US-20060223837-A1 | Biaryl derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-10-05 | — | — | US | disclosed |
| WO-2006102645-A1 | BIARYL DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223837-A1 | Biaryl derived amide modulators of vanilloid VR1 receptor | TRPV1, TRPV2, CNR1 | ALDH1A1 1031/4885HPGD 1759/4885PLAU 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.